Researchers at UCLA, collaborating with scientists worldwide, have identified a promising new treatment that can detect, kill, and reprogram aggressive, treatment‑resistant cancers such as osteosarcoma and glioblastoma.
Published in Signal Transduction and Targeted Therapy, the study outlines a novel approach that employs a custom antibody, DUNP19, to bind a surface protein called LRRC15, found on selected malignant cells and the surrounding stromal cells. By attaching radioactive particles to the antibody, scientists can image tumors with precision and deliver radiation directly to malignant tissue, sparing healthy cells.